National Council for Prescription Drug Programs indexing - billing unit
- Manufacturer
- National Council for Prescription Drug Programs
- Effective date
- 2012-07-24
- Label type
- Indexing - Billing Unit
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-05 01:55:06
Label at a glance#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0944-2884-01 | EA - Each | 0944-2884 | 6234ccee-dced-4f84-83a1-e59f978225ba | 1 | 2012-07-24 |
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 0944-2884 | 0944-2884-01 |
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125325 | Glassia | Alpha-1-Proteinase Inhibitor (Human) | 351(a) | Rx | 2026-10-01 |
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| GLASSIA | ALPHA.1-PROTEINASE INHIBITOR HUMAN | Takeda Pharmaceuticals America, Inc. | 83473cbb-48e4-42a2-81b6-4c851423da7b | 2025-12-02 | Warnings, Adverse reactions | 0944-2884-01 00944288401 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.